文献速递腹部

基于影像组学的机器学习预测胃癌患者新辅助化疗反应及生存预后的诊断准确性:系统评价与Meta分析

Diagnostic accuracy of radiomics-based machine learning for neoadjuvant chemotherapy response and survival prediction in gastric cancer patients: A systematic review and meta-analysis.
PubMed 文献 · Eur J Radiol · 2023-12-05

该系统评价与Meta分析纳入14项研究、3373例接受新辅助化疗的胃癌患者,评估影像组学预测化疗反应与生存的准确性。验证队列中,仅用影像组学特征预测化疗反应的c-index为0.750,敏感度0.67、特异度0.77;临床数据联合影像组学特征后c-index升至0.814,敏感度0.78、特异度0.73。作者认为影像组学有潜力无创预测局部晚期胃癌患者的新辅助化疗反应和生存结局。

要点

  • 验证队列中仅用影像组学特征预测新辅助化疗反应:c-index 0.750,敏感度0.67,特异度0.77。
  • 临床数据联合影像组学特征后预测性能提升:c-index 0.814,敏感度0.78,特异度0.73。
  • 全部研究平均RQS评分为36.3%(范围0–63.9%),作者强调需未来多中心研究。

核心结论

  • 影像组学有潜力无创预测局部晚期胃癌患者的新辅助化疗反应和生存结局,作者强调需要未来多中心研究并开发影像来源的风险分层工具。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Cochrane、Embase和Web of Science数据库截至2023年2月21日,纳入14项研究共3373例接受新辅助化疗的胃癌患者,采用影像组学质量评分(RQS)工具评估研究质量。

诊断标准与关键数值

  • 验证队列中仅以影像组学特征为建模变量预测新辅助化疗反应:c-index 0.750(95%CI 0.710–0.790),敏感度0.67(95%CI 0.58–0.75),特异度0.77(95%CI 0.69–0.84)。
  • 验证队列中临床数据联合影像组学特征为建模变量预测新辅助化疗反应:c-index 0.814(95%CI 0.780–0.847),敏感度0.78(95%CI 0.70–0.84),特异度0.73(95%CI 0.67–0.79)。
  • 全部研究平均RQS评分为36.3%,范围0–63.9%。

局限性

  • 全部研究平均RQS评分为36.3%,范围0–63.9%,提示纳入研究方法学质量有限。
  • 作者在结论中强调需要未来多中心研究并开发影像来源的风险分层工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: In recent years, researchers have explored the use of radiomics to predict neoadjuvant chemotherapy outcomes in gastric cancer (GC). Yet, a lingering debate persists regarding the accuracy of these predictions. Against this backdrop, this study was conducted to examine the accuracy of radiomics in predicting the response to neoadjuvant chemotherapy in GC patients.

METHODS: An exhaustive search of relevant studies was conducted in PubMed, Cochrane, Embase, and Web of Science databases up to February 21, 2023. The radiomics quality scoring (RQS) tool was employed to assess study quality. Tumor response to neoadjuvant chemotherapy and survival outcomes were examined as outcome measures.

RESULTS: Fourteen studies involving 3,373 GC patients who had received neoadjuvant chemotherapy were incorporated in our meta-analysis. The mean RQS score across all studies was 36.3%, ranging between 0 and 63.9%. On the validation cohort, when the modeling variables were restricted to radiomic features alone, the predictive performance was characterized by a c-index of 0.750 (95% CI: 0.710-0.790), with a sensitivity of 0.67 (95% CI: 0.58-0.75) and a specificity of 0.77 (95% CI: 0.69-0.84) for the prediction of neoadjuvant chemotherapy response. When clinical data was integrated with radiomic features as modeling variables, the predictive performance improved, yielding a c-index of 0.814 (95% CI: 0.780-0.847), a sensitivity of 0.78 [95% CI: 0.70-0.84], and a specificity of 0.73 [95% CI: 0.67-0.79].

CONCLUSIONS: Radiomics holds promise to noninvasively predict neoadjuvant chemotherapy response and survival outcomes among patients with locally advanced GC. Additionally, we underscore the need for future multicenter studies and the development of imaging-sourced tools for risk stratification in this patient population.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Adili D, Mohetaer A, Zhang W, et al. Diagnostic accuracy of radiomics-based machine learning for neoadjuvant chemotherapy response and survival prediction in gastric cancer patients: A systematic review and meta-analysis. Eur J Radiol. 2023. PMID: 38382422. doi:10.1016/j.ejrad.2023.111249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。